

BioCell Your Trusted Supplier of *in vivo* MAbs
 α -PD-1 · α -PD-L1 · α -CTLA-4 · α -CD20 · α -NK1.1 · α -IFNAR-1

DISCOVER MORE



Barcoding of Live Human Peripheral Blood Mononuclear Cells for Multiplexed Mass Cytometry

This information is current as of August 4, 2022.

Henrik E. Mei, Michael D. Leipold, Axel Ronald Schulz, Cariad Chester and Holden T. Maecker

J Immunol 2015; 194:2022-2031; Prepublished online 21 January 2015;

doi: 10.4049/jimmunol.1402661

<http://www.jimmunol.org/content/194/4/2022>

Supplementary Material <http://www.jimmunol.org/content/suppl/2015/01/20/jimmunol.1402661.DCSupplemental>

References This article **cites 25 articles**, 3 of which you can access for free at: <http://www.jimmunol.org/content/194/4/2022.full#ref-list-1>

Why *The JI*? Submit online.

- **Rapid Reviews! 30 days*** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

**average*

Subscription Information about subscribing to *The Journal of Immunology* is online at: <http://jimmunol.org/subscription>

Permissions Submit copyright permission requests at: <http://www.aai.org/About/Publications/JI/copyright.html>

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: <http://jimmunol.org/alerts>

The Journal of Immunology is published twice each month by
The American Association of Immunologists, Inc.,
1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 2015 by The American Association of
Immunologists, Inc. All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.



Barcoding of Live Human Peripheral Blood Mononuclear Cells for Multiplexed Mass Cytometry

Henrik E. Mei,* Michael D. Leipold,* Axel Ronald Schulz,*¹ Cariad Chester,*[†] and Holden T. Maecker*

Mass cytometry is developing as a means of multiparametric single-cell analysis. In this study, we present an approach to barcoding separate live human PBMC samples for combined preparation and acquisition on a cytometry by time of flight instrument. Using six different anti-CD45 Ab conjugates labeled with Pd104, Pd106, Pd108, Pd110, In113, and In115, respectively, we barcoded up to 20 samples with unique combinations of exactly three different CD45 Ab tags. Cell events carrying more than or less than three different tags were excluded from analyses during Boolean data deconvolution, allowing for precise sample assignment and the electronic removal of cell aggregates. Data from barcoded samples matched data from corresponding individually stained and acquired samples, at cell event recoveries similar to individual sample analyses. The approach greatly reduced technical noise and minimizes unwanted cell doublet events in mass cytometry data, and it reduces wet work and Ab consumption. It also eliminates sample-to-sample carryover and the requirement of instrument cleaning between samples, thereby effectively reducing overall instrument runtime. Hence, CD45 barcoding facilitates accuracy of mass cytometric immunophenotyping studies, thus supporting biomarker discovery efforts, and it should be applicable to fluorescence flow cytometry as well. *The Journal of Immunology*, 2015, 194: 2022–2031.

Phenotypic and functional assessments of leukocytes are frequently used by clinicians and researchers to analyze the state of the immune system, to detect specific aberrations, and for biomarker discovery. Mass cytometry, a hybrid technology permitting single-cell cytometry based on a mass spectrometric readout, allows for massively multiparametric single-cell analysis (1, 2). The technology is capable detecting >35 markers of interest as well as dead cell exclusion and DNA detection (used to identify intact cell events), thereby more than doubling the number of analytes typically measured by conventional flow cytometry (3, 4). Mass cytometry can thus be a key technology to recent efforts to systematically study the human immune system (5) in

the context of health, aging, vaccination, immunopathology, and medical treatment.

Conventional flow cytometry is subject to large-scale standardization efforts with the aim of enhancing comparability of data that are raised in different contexts (6, 7). For mass cytometry, variability in the machine performance (1) as well as in the sample preparation and staining procedure can be partially overcome by daily tuning of the cytometry by time of flight (CyTOF) mass cytometer (8) and by using normalization beads (9). However, standardization of mass cytometry experiments that involve the comparison of multiple samples or stimulation conditions should ideally be based on exactly identical conditions for sample preparation and acquisition. Running a series of individual samples as a composite barcoded sample eliminates concerns regarding potentially different conditions during sample preparation and acquisition, eliminates sample-to-sample carryover problems, and reduces reagent consumption (10, 11).

Cell barcoding is achieved by using mass-tagged thiol- or amine-reactive barcode reagents (12–16), which require cell fixation and at least partial permeabilization of the cell membrane.

In contrast, in this study we describe a sample barcoding approach for human PBMC using cell surface CD45 staining to allow barcoding of live cells prior to surface staining. Six differently mass-tagged CD45 Abs were used to barcode up to 20 PBMC samples in a combinatorial fashion prior to their joint surface and intracellular staining with immunophenotyping Ab, fixation, permeabilization, and sample acquisition on the CyTOF instrument.

Four of the six barcoding Abs are labeled with Pd isotopes that are detected outside the mass range normally used for analyte-specific probes. In contrast to a previous approach to label Ab with Pd that led to reagents that stain dead cells (17), we used isothiocyanobenzyl-EDTA (SCN-Bn-EDTA) to achieve labeling of Ab with Pd (14, 16).

Single-sample data extracted from the acquired composite sample reproduced results from separately stained and acquired samples, and Boolean data deconvolution permitted electronic removal of cell aggregates containing cell events with two or more different barcodes.

*Human Immune Monitoring Center, Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA 94305; and [†]Department of Oncology, Stanford University School of Medicine, Stanford, CA 94305

¹Current address: Berlin-Brandenburg Center for Regenerative Therapies, Charité University Medicine, Campus Virchow Klinikum, Berlin, Germany.

Received for publication October 20, 2014. Accepted for publication December 10, 2014.

This work was supported by National Institute of Allergy and Infectious Diseases/National Institutes of Health Grants 5U19AI057229, 5U19AI090019, and S10RR027582. H.E.M. was supported by a fellowship from the Deutscher Akademischer Austauschdienst (Bonn, Germany) and is supported by a fellowship from the Deutsche Forschungsgemeinschaft (Grant ME 3644/2-1).

H.E.M. conceived and performed experiments with C.C., analyzed results, and made the figures; M.D.L. made the SCN-Bn-EDTA reagents and performed experiments; A.R.S. was involved in initial testing of CD45 Ab conjugates; H.E.M., M.D.L., and H.T.M. planned research; H.E.M. and H.T.M. wrote the manuscript; M.D.L., C.C., and A.R.S. discussed results and edited the manuscript.

Address correspondence and reprint requests to Dr. Henrik E. Mei, Human Immune Monitoring Center, Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, 299 Campus Drive, Fairchild Science Building, Room D033, Stanford, CA 94305. E-mail address: hemei@stanford.edu

The online version of this article contains supplemental material.

Abbreviations used in this article: CV, coefficient of variation; CyTOF, cytometry by time of flight; mDC, myeloid dendritic cell; pDC, plasmacytoid dendritic cell; SCN-Bn-EDTA, isothiocyanobenzyl-EDTA.

Copyright © 2015 by The American Association of Immunologists, Inc. 0022-1767/15/\$25.00

Materials and Methods

Reagents

Millipore filtered deionized water was used as sample carrier and to prepare 1× PBS from 10× PBS (Rockland Immunochemicals, Gilbertsville, PA) and CyPBS/0.1% BSA (Sigma-Aldrich) (CyPBS/BSA) buffer that was used as staining and washing media for PBMC. For some experiments, CyPBS/BSA was supplemented with 0.05% (v/v) sodium azide (Teknova, Hollister, CA) and 2 mM EDTA (Hofer, Holliston, MA). Buffers were filtered over 0.22- μ m membranes (Pall, Ann Arbor, MI, or EMD Millipore, Billerica, MA). Unlabeled, carrier protein-free Abs (Supplemental Table 1) were purchased from BioLegend (San Diego, CA), BD Biosciences (San Jose, CA), Santa Cruz Biotechnology (Dallas, TX), R&D Systems (Minneapolis, MN), and Miltenyi Biotec (San Diego, CA). In-house conjugations were carried out using MaxPar kits (Fluidigm, Sunnyvale, CA) according to the manufacturer's instructions. This includes CD45-In113 and CD45-In115 barcoding agents. Highly isotopically enriched metal salts not available through Fluidigm were purchased from Trace Sciences (Richmond Hill, ON, Canada). Abs were diluted to working concentrations in CyPBS/BSA and filtered over 0.1- μ m spin filters (Amicon, Millipore).

PBMC

PBMC were prepared from whole blood or from Trima Accel leukoreduction system chamber content (Terumo BCT, Lakewood, CO) obtained from Stanford Blood Center by gradient centrifugation over Ficoll medium (GE Healthcare, Uppsala, Sweden), washed, and cryopreserved according to standard procedures (<http://iti.stanford.edu/himc/documents/SOP-PBMCDirectFicollHeparinV1-4-1.pdf>). Frozen PBMC were kept in vapor phase liquid nitrogen for longer term storage. For experiments, PBMC samples were thawed in a 37°C water bath and washed twice in RPMI 1640 (HyClone; Thermo Scientific, Waltham, MA) supplemented with 10% FBS (Atlanta Biologicals, Flowery Branch, GA) in 15 ml Falcon tubes (BD Biosciences), penicillin and streptomycin, and 10 U/ml benzoylase (Sigma-Aldrich), resuspended in PBS, and kept on ice for further use. PBMC were counted and checked for viability using a Viacell counter (Beckman Coulter, Brea, CA). PBMC viability was typically >95%. Blood sample donors were enrolled under Institutional Review Board protocol no. 31256.

Pd barcoding reagents

SCN-Bn-EDTA was loaded with Pd ions as described (14, 16). Ten milligrams SCN-Bn-EDTA (Dojindo, Santa Clara, CA) chelator was dissolved in 1 ml L buffer (Fluidigm) by vortexing and warming in a water bath. To load the chelator with Pd ions, 28.5 μ l 100 mM solution of isotopically enriched Pd nitrate (Trace Sciences) in 5 N HCl was added to the 22.8 mM SCN-Bn-EDTA solution to achieve a molar chelator/metal ratio of 2:1. After mixing and incubation for 1 min, aliquots were snap-frozen in liquid nitrogen and lyophilized overnight in a benchtop freeze-dryer (Labconco, Kansas City, MO). Lyophilized products were dissolved in DMSO (Sigma-Aldrich) to yield a 10 mM solution and were kept at -20°C until use.

Fifty micrograms CD45 Ab (clone HI30; BioLegend) was washed two to three times with 350 μ l CyPBS over a 30-kDa spin filter (Amicon, EMD Millipore) for 10 min at 4°C and 17,500 \times g. Pd-loaded SCN-Bn-EDTA stock was thawed and 6.4 μ l was added to the Ab dissolved in a total of 313 μ l PBS, mixed by pipetting, and incubated for 1 h at 37°C in a water bath.

The conjugate was washed at least three times with 300 μ l CyPBS over a 30-kDa spin filter for 10 min at 4°C and 17,500 \times g, then transferred to a 1.6-ml microcentrifuge tube. Protein concentration was quantified by NanoDrop (Thermo Fisher, Waltham, MA) at 280 nm, and Ab stabilizer (Candor Biosciences, Wangen, Germany) was added to the Ab preparation to a final concentration of 50%. Abs were kept at 4°C.

The kinetics of Ab labeling with Pd-loaded SCN-Bn-EDTA were investigated in a time course experiment, revealing that most labeling occurs within a few minutes after mixing (Supplemental Fig. 1A). Few if any metal ions bound nonspecifically to the Ab, as washing the Ab conjugate with counter chelators (three washes with 300 μ l each wash over a 30-kDa spin filter with 5 mM nitrilotriacetic acid [Sigma-Aldrich] or 44 mM *N*-(2-hydroxyethyl)iminodiacetic acid [Dojindo]) did not suppress the signal of a CD45-Pd106 staining (Supplemental Fig. 1B). This confirms that Pd labeling of Ab was achieved by Pd ions complexed by EDTA with high-affinity interactions rather than by nonspecific, lower affinity interactions.

Barcoding and immunophenotyping of PBMC

Individual CD45 Ab conjugates were diluted in CyPBS/BSA to 3 \times the working concentration (2–5 μ g/ml) in the final barcoding reaction on 0.1- μ m spin filters. An example of a titration experiment is shown in

Supplemental Fig. 1C for CD45-Pd106. After centrifugation (17,500 \times g, 10 min, cooled benchtop centrifuge; Eppendorf, Hauppauge, NY), filtered Abs were used to prepare up to 20 barcoding mixes in a 96-well U-bottom polystyrene microtiter plate (Corning, Tewksbury, MA).

For barcoding, 7.5 \times 10⁵ cells from individuals PBMC samples were pelleted in cavities of a 96-well polypropylene V-bottom 2-ml-deep well block (Corning) and stained with 20 μ l premade combinations of 0.1- μ m-filtered CD45 Ab for 20 min at 4°C. For some reagent validation experiments, 1.5 ml polypropylene Eppendorf tubes (Eppendorf) were used as reaction vessels. Afterward, PBMC were washed twice in 1 ml CyPBS/BSA, resuspended in CyPBS/BSA, combined into a single well, spun down (10 min, 483 \times g), and subjected to staining with a 50 μ l surface Ab mixture for 45 min at 4°C. Afterward, the sample convolute (up to 1.5 \times 10⁷ cells) was washed twice in 1 ml CyPBS/BSA, once in 1 ml CyPBS, and subjected to a protocol for dead cell identification modified from Fienberg et al. (18). Briefly, cisplatin (Enzo Life Sciences, Farmingdale, NY) 100 mM stock solution in DMSO was thawed and diluted to 25 μ M solution in CyPBS. Cell pellets were resuspended in 100 μ l cisplatin solution for 1–2 min (in one experiment, 5 min) and the reaction was stopped by mixing with 1 ml RPMI 1640/15% FBS and centrifuging at 800 \times g for 10 min. Cells were then washed once in 1 ml CyPBS/BSA, once in 1 ml CyPBS, and fixed for 20 min at room temperature in 100 μ l 2% formaldehyde solution freshly diluted with CyPBS from 16% stock ampules (Electron Microscopy Sciences, Hatfield, PA, or Alfa Aesar, Ward Hill, MA). PBMC were then washed twice (10 min, 800 \times g) in 1 ml CyPBS/BSA and permeabilized in 100 μ l 1 \times saponin solution freshly made with CyPBS from 10 \times concentrate (1% saponin concentration; Affymetrix, Santa Clara, CA) for another 20 min at room temperature. After washing PBMC once in CyPBS/BSA, the pellet was resuspended with a 50 μ l mixture containing Ab against intracellular targets diluted in CyPBS/BSA and filtered through a 0.1- μ m spin filter prior to use. After 20 min incubation at 4°C, cells were washed in CyPBS/BSA and stored overnight at 4°C in CyPBS/BSA. The next day, cells were washed in CyPBS prior to 20 min incubation at room temperature with iridium intercalator (Fluidigm) diluted in CyPBS per the manufacturer's instructions. Thereafter, PBMC were washed twice in 1 ml CyPBS/BSA, optionally once in CyPBS, and twice in 500 μ l water. For acquisition of barcoded cell samples on CyTOF, PBMC were resuspended in 1 ml water supplemented with EQ four-element calibration beads (Fluidigm), and 100- μ l portions of the suspension were further diluted 1:20 (v/v) with bead/water solution prior to filtering through a 35- μ m mesh and injecting into the instrument in 500- μ l volumes. Supernatants were aspirated using a pipette or vacuum manifold throughout the protocol.

Additional PBMC samples used for validation of Ab and head-to-head comparisons were processed in a similar way, using 20- μ l staining volumes of Ab mixture instead of 50- μ l volumes.

Mass cytometry

The CyTOF instrument (version 1, Fluidigm) was started, tuned, and cleaned as described before on a daily basis (8), using tuning and wash solution (Fluidigm). Ultrapure argon was supplied by Praxair (Danbury, CT). The spray chamber was cleaned daily with water and dried with laboratory air. Cells were injected as a single-cell suspension in water or water supplemented with EQ four-element calibration beads (Fluidigm) after filtration through a 35- μ m nylon mesh (cell strainer cap tubes; BD Biosciences) immediately prior to acquisition. Data were acquired in Dd "internal" calibration mode, with noise reduction turned off and lower and upper cell length parameter values set to 10 and 75, respectively. FCS files were generated by CyTOF instrument control software v5.1.602 (Fluidigm), which also served to control the instrument. Calibration bead signals were used to monitor the detector performance over the runtime. Because no major variation was noted (Fig. 3A), we chose not to normalize the data using calibration beads. Samples were injected into the sample loop in portions of 500 μ l every ~8 min and cells were filtered over a 35- μ m mesh prior to every other injection. One- and 3-ml syringes (Norm-Ject; Henke Sass Wolf, Tuttlingen, Germany) were used to inject samples or accessory liquids.

Data analysis and presentation

FlowJo software (v9.6.4–9.7.6; Tree Star, Ashland, OR) was used to concatenate, deconvolute, analyze, and display data, with log parameter ranges set to 20,000, axes displaying 5-log decades and width basis set to -20.

Data from barcoded composite samples were deconvoluted using a Boolean gating strategy based on bivariate distribution of cells over signal intensities of CD45 staining used for barcoding. In experiments used for Fig. 1, sample-to-sample carryover events were electronically excluded from analyses by electronic exclusion of events that showed bright signals

in mass detection channels that were not used in the particular experiment. For some analyses, deconvoluted data were exported by FlowJo and reimported as single files. In case of unintended interruption of mass cytometry measurements, multiple FCS files were collected per sample, which were concatenated using FlowJo. Cell frequencies and signal intensities were determined using FlowJo, and coefficients of variation (CV) were calculated in MS Excel using $CV = SD[\text{data set}] / \text{Abs}(\text{average}[\text{data set}])$.

GraphPad Prism 6 (GraphPad Software, San Diego, CA) was used to analyze data. Excel for Mac 2011 v14.4.4 (Microsoft, Redmond, WA) was used to generate heat maps. ChemBioDraw v13.0 (PerkinElmer, Waltham, MA) was used for the illustration in Fig. 1A, and Powerpoint (Microsoft) and Illustrator CS4 (Adobe, San Jose, CA) were used for assembling figures.

Results

Pd labeling of CD45 Abs

In the interest of maintaining the number of cytometric channels for analytes of interest, we chose to make reagents that permit the

exploitation of hitherto unused mass detection channels of the CyTOF instrument. Different from a previous approach to generate Pd-labeled Ab (17), we used SCN-Bn-EDTA, an amine-reactive compound carrying EDTA as a metal ion chelating moiety, to generate a series of CD45 Abs labeled with highly isotopically pure palladium ions (Pd104, Pd106, Pd108, and Pd110) (Fig. 1A). SCN-Bn-EDTA was loaded with Pd ions in aqueous solution at 0.5 equivalents, lyophilized, and redissolved in DMSO for long-term storage at -20°C (14, 16). The Pd-loaded compound was used to label CD45 Abs by targeting the Ab's primary amines (detailed in *Materials and Methods*). Inhibition of the CD45-Pd conjugate signals by preincubation of PBMC with excess unlabeled CD45 Ab or differently labeled CD45 Ab prior to incubation with CD45-Pd conjugates demonstrates that Pd-labeled CD45 Abs retained their specificity for CD45 (Fig. 1B, Supplemental Fig. 1D, 1E). Ab labeling with In113 and In115 was carried out using MaxPar la-




FIGURE 1. Production and validation of CD45 Ab conjugates used for barcoding. **(A)** Workflow for the generation of Pd-labeled CD45 Abs using SCN-Bn-EDTA. The blue box reflects SCN-Bn-EDTA, the structure of which is depicted in the blue inset. **(B)** CD45 Ab retains specificity after Pd labeling. PBMC were stained with CD45-Pd106 with or without prior incubation with excess unlabeled CD45 Ab and analyzed by mass cytometry. Numbers reflect geometric mean signal intensities. **(C)** PBMC were stained with one or combinations of up to three different CD45 Abs labeled with the indicated metal ions. Numbers reflect geometric mean signal intensities. The background visible in the control not stained for CD45-In115 results from isotopic impurity of In113 used in the staining with CD45-In113.




FIGURE 3. Boolean deconvolution of the barcoded sample convolute. Representative analysis of a convolute of barcoded samples. Twenty different PBMC samples were CD45 barcoded as illustrated in Fig. 2, combined and further processed and acquired as one single sample. **(A)** During the acquisition time of the barcoded sample convolute, signal intensities were stable as demonstrated for three different mass channels reflecting the expression of HLA-DR, CD20, and CD14. The channel used for HLA-DR detection was also occupied by normalization beads containing Lutetium, which appear as a horizontal streak at a signal intensity of ~ 5000 . **(B)** Of all acquired events, beads were excluded from the analysis, and only nucleated (DNA-“positive”) cell events were further analyzed. After strict gating for nucleated events excluding events showing either very high or low 193Ir/191Ir signals resulting from staining with an Ir-loaded DNA intercalator, analysis was additionally restricted to events with a cell length parameter value < 50 . **(C)** The remaining cell events were gated according to CD45 signals in six different channels and split into “positive” and “negative” subsets. **(D)** Annotated screenshot from a FlowJo workspace illustrating the deconvolution of data. After initial gating as shown in (A) and bivariate gating in CD45 channels (B), Boolean gates were generated to reflect all possible barcode combinations, 20 of which were actually used (Slot01...Slot20), leaving 44 unused or “illegal” barcodes (Z01...Z44). Plus and minus signs were used in each line to identify the actual barcode combination in an ascending order of the mass label (104-106-108-110-113-115).

frequencies of CD20⁺ B cells among CD45⁺ cells determined in the barcoded samples largely matched those from nonbarcoded samples. Correlation of cell frequency data were maintained when IgA⁺ and IgD⁺ subsets of B cells were analyzed, representing a smaller and a larger subpopulation of CD20⁺ B cells, respec-

tively (Fig. 4B). In one experiment, frequencies of type 2 BDCA-3⁺ myeloid dendritic cells (mDC; CD45⁺BDCA-3⁺) (19) as well as basophils (CD3⁻CD20⁻CD33⁻CD14⁻CD123⁺Syk^{low}HLA-DR⁻) and CD3⁻CD20⁻CD33⁻CD14⁻CD123⁺Syk^{high}HLA-DR⁺ plasmacytoid dendritic cells (pDC) were analyzed to address data

Table I. Runtime and cell recoveries in three CD45 barcoding validation experiments

	No. of Samples Barcoded	No. of Cell Events Acquired ^a	Runtime of the Barcoded Convolute (min) ^b	Cells Recovered per Barcoded Sample
Experiment 1	20	1,676,767	198	45,139 (28,140–58,559)
Experiment 2	14	1,420,057	183	33,013 (9,060–61,348)
Experiment 3	20	2,235,999	220	51,193 (5,891–92,027)

^aThis number reflects DNA⁺ events; calibration beads and debris were excluded.

^bIn all three experiments, the acquisition was terminated while $> 50\%$ of the sample was left.




FIGURE 4. Data recovered from CD45-barcoded and then deconvoluted samples recapitulate data of nonbarcoded PBMC samples. Fourteen or twenty unique PBMC samples were CD45 barcoded and combined into one single sample. Aliquots of the identical samples were processed as individual samples. Both individual samples and the CD45-barcoded sample convolute were stained with the identical Ab mixture using the same protocol in each experiment (except for an additional water wash of the barcoding sample prior to injection). They were acquired on the same day on the same mass cytometer. Results from three independent experiments are shown. **(A)** Histogram overlays depict CD20 expression of all individually acquired samples in a particular experiment (*left*, colored histograms) and the corresponding CD45-barcoded and deconvoluted samples (*right*, colored histograms). The bold black histogram is identical in each pair of corresponding plots and depicts the CD20 expression of all barcoded samples together. **(B)** Frequencies of CD20⁺ B cells among CD45⁺ cells as well as frequencies of IgA⁺ and IgD⁺ B cells among CD20⁺ B cells were determined as shown in the dot plots on top of the figure in both CD45-barcoded/deconvoluted as well as individually processed and run samples. The graphs compare cell frequencies obtained in barcoded versus individual measurements for each of the three experiments. Each dot represents a unique PBMC sample. The *r* and *p* values resulting from Spearman correlation analyses as well as slopes resulting from linear regression (with the line forced through *x* = 0, *y* = 0) are included along with each graph. **(C)** Median signal intensities for various surface or intracellular markers were determined in total CD20⁺ B cells, IgA⁺ B cells, and IgD⁺ B cells in barcoded and corresponding individual samples. The *r* and *p* values from Spearman correlation analyses between barcoded and individual samples were used to generate heat maps, where red color indicates high *r* values or low *p* values. Data were grouped according to whether a particular marker is commonly expressed by human peripheral blood B cells. Within both groups, data are sorted from left to right according to ascending atomic mass of the reporter metal used.

reproducibility of extremely rare cell subsets. Despite their low frequencies among total CD45⁺ cells (at averages of <0.01% for BDCA-3⁺ mDC, <0.5% for basophils, and <0.4% for pDC), data were well correlated (Spearman correlation analysis, BDCA-3⁺ mDC, *r* = 0.81, *p* < 0.0001; basophils, *r* = 0.64, *p* = 0.002; and pDC, *r* = 0.78, *p* < 0.0001). Also, distinctive features of individual PBMC samples such as exceptionally low expression of CD33 by monocytes can be reliably traced and reproduced in the barcoded sample data (Supplemental Fig. 3; e.g., sample no. 10 in Supplemental Fig. 3A).

Signal intensities were determined in several subsets of monocytes, T cells, and B cells. Fig. 4C depicts correlation analyses for total, IgA⁺, and IgD⁺ B cells for several molecules that are known to be expressed by, or absent from, B cells. Good correlations between barcoded and individually measured sample data were seen for Abs detecting Ags that are known to be expressed by B cells (such as HLA-DR, CD19, CD20, CD32, CD85j, and Syk), but generally not for unused channels (Cd112, Eu151; not shown) or unrelated markers (e.g., CD33, CD3, CD4, CD8, CD28, CD161, TCRγδ, CD45RO, or CD16) (Fig. 4C). Of note, signal intensity correlations in IgA⁺ B cells were good and comparable to those of more abundant cell subsets, despite the

scarcity of IgA⁺ B cell events, on average (representing 0.41–0.57% of total CD45⁺ cells, or between 146 and 325 cell events in an individual sample file).

We also assessed markers commonly expressed by monocytes such as CD33, CD32, Syk, HLA-DR, CD11c, and CD14; these were found to correlate between barcoded and nonbarcoded samples when monocytes were gated (according to CD33 and CD14 expression). Similar results were found for T cell markers (e.g., CD28, CD45RA, CD45RO, CD4, CD25, and CD27) when T cells were gated (CD3⁺CD4⁺ and CD3⁺CD8⁺ T cells; data not shown). Overall, high average signal intensity shown by a marker in a particular cell subset selected for better correlation (as judged by high Spearman *r* value and low *p* value) compared with lower signal intensity parameters (data not shown).

CD45 barcoding resulted in visibly less sample-to-sample variation of the general staining pattern (Fig. 4A), but also of CV of signal intensity data of barcoded compared with individually processed and acquired data sets (Fig. 5A). Overall, 88.9% of 757 pairwise comparisons between signal intensity data showed smaller CV in the barcoded version. The median CV was 20.9% in the barcoded samples compared with 44.2% in the data sets of individually processed samples (*p* < 0.0001, Wilcoxon test). The




FIGURE 5. CD45 barcoding reduces technical variation in mass cytometry data sets. CV of analyte-specific median signal intensity data were determined for each series of cell subsets in the three experiments shown in Fig. 4. These comprise CD4⁺ and CD8⁺ T cells, IgD⁺ and IgA⁺ B cells, as well as total CD45⁺ cells and monocytes gated according to CD33/CD14 or CD32/Syk expression. Data from CD123⁺ and BDCA-3⁺ cell subsets were additionally considered in one experiment. The CV from barcoded analyses were plotted against the CV from individual analyses. Only data with an average signal intensity value of >1 were considered, to avoid near-zero problems resulting from division by very small values in the determination of CV. Empty mass channels and channels reflecting DNA intercalator or cisplatin staining were not considered either. Thus, a total of 757 datum points are shown in (A), representing 82% of the entire data set. A diagonal is shown for orientation. Data sets with lower CV in individually measured samples compared with barcoded samples locate below the diagonal, and data sets with lower CV in barcoded samples locate above the line. (B) Two examples extracted from the overall analysis illustrate reductions of CV in cases representing specific staining (*left panel*, CD32 signal of IgA⁺ B cells) or background staining (*right panel*, Syk signal of CD3⁺ T cells).

CD45 barcoding-related improvement in the CV was due to both reductions in CV of specific as well as background staining (Fig. 5B).

In summary, biological sample characteristics were maintained when PBMC were stained and acquired as a barcoded composite sample. At the same time, CD45 barcoding largely reduced data variability by harmonizing sample preparation and acquisition conditions.

Removal of aggregates and cell recovery

The exclusion of cell events not meeting the requirements of any of the barcode slots (Fig. 2) depletes cells that carry either more or less than three different CD45 labels. This strategy obviously selects directly against cell events that comprise data from two (or more) actual cells carrying different barcodes (intersample doublets). Such cells always yield a combination of at least four different CD45 signals and are therefore excluded during data deconvolution. Additionally, CD45 barcoding minimized the presence of intrasample cell doublets in the deconvoluted data (see *Discussion*), as revealed by analyzing frequencies of cells with simultaneous staining of different, mutually exclusive cell lineage markers such as combinations of CD3, CD14, and CD20 (Fig. 6). For example, even after applying strict pregating routinely used to deplete cell aggregates (gating 1, *upper panel* in Fig. 6A), CD45 barcoding reduced the frequencies of CD14⁺CD20⁺ events to averages of 0.02, 0.08, and 0.16% in the three different sets of barcoded samples. This is in comparison with 0.21, 0.24, and 0.32% in the cell population that was excluded due to carrying more than three CD45 labels and to 0.10, 0.09, and 0.11% in individually acquired samples analyzed using a similar gating strategy, respectively. Events excluded due to carrying less than three different CD45 labels contained very low frequencies of cell doublets. Similar analyses of CD3⁺CD20⁺ and CD3⁺CD14⁺ doublet populations confirmed these overall results. Based on that, we tested whether CD45 barcoding alone was sufficient to remove intrasample cell doublets from the sample convolute. When applying stepwise less stringent pregating whose main purpose is to exclude cell doublets, CD45 barcoding alone resulted in a similar removal of aggregates compared with use of DNA and cell length parameter gates and also allowed for similar cell recovery as

compared with individually run samples. Using wide DNA and cell length gates (Fig. 6A, gating 4), recoveries were 55.3, 37.9, and 48.7%, matching the average recovery of ~50% typically achieved in individual, nonbarcoded measurements. In summary, CD45 barcoding efficiently eliminates cell doublet events and selects for live cells while cell recoveries similar to those of individual measurements can be achieved.

Discussion

Fluorescent barcoding has been used successfully in conventional flow cytometry (20–22), and the strategy has been recently applied to mass cytometry, using metal-loaded, thiol-reactive compounds used for intracellular staining, after cell fixation and permeabilization (13). In the present study, we describe a barcoding technique for mass cytometry experiments using differently labeled Abs directed against cell surface-expressed CD45, allowing for barcoding of live CD45-expressing cells. Four of the six different CD45 Abs occupy Pd channels outside the hitherto used channels of the CyTOF instrument, leaving the core window between atomic masses 139 and 176 for analyte-specific reagents. Additionally, owing to the barcoding reagent mass labels used, interferences between signals from barcode stainings and analyte detection (such as +1 spillover or +16 oxide formation) are technically impossible. Pd- and In-labeled CD45 Abs were used during weeks to months without notable loss of staining intensity and were kept in aqueous buffer at 4°C, allowing for easier reagent handling as compared with hydrolysis-sensitive maleimido-monoamide-DOTA compounds used previously (13). A previously described protocol to label Ab with Pd appeared to be more time-consuming and difficult to perform in a laboratory not set up for chemical syntheses (17). In contrast, the protocol described in the present study to generate barcoding Ab is comparably simple and can be performed within 2 d, using commercially available materials and predominantly standard laboratory equipment.

The ability to barcode live cells prior to any fixation and permeabilization permits unequivocal surface staining of Ags at identical quality and staining patterns as in routine PBMC analyses. In contrast, alternative cell barcoding protocols (13–16, 20) required fixation and at least partial permeabilization of cells prior to barcoding. Because fixation (commonly with paraformalde-




FIGURE 6. CD45 barcoding removes doublet cell events. The presence of cell doublets was traced for the example of events showing simultaneous expression of the monocyte marker CD14 and the B cell marker CD20 in three independent experiments. One representative data set is shown. **(A)** Four different gating strategies applied to the sample convolute prior to CD45 gating and deconvolution were compared, differing in the stringency of DNA and cell length parameter gating (gating 1, small DNA gate, length restriction; gating 2, small DNA gate, no cell length restriction; gating 3, wide DNA gate, cell length restriction; gating 4, wide DNA gate, no length restriction). Biaxial dot plots showing CD14 versus CD20 expression with a gate set on CD14⁺ CD20⁺ doublet events are shown for pre-gated cells prior to deconvolution, as well as after deconvolution, for barcoded samples (corresponding to all cells from merged data from Slot01 through Slot20, illustrated in Fig. 3D), and for cell events excluded during deconvolution due to carrying either more (merged Z01 through Z22 in Fig. 3D) or fewer (merged Z23-Z44) than three CD45 labels, respectively. **(B)** Summary graph depicting the presence of CD20⁺CD14⁺ events in barcoded samples and cells excluded during deconvolution. Individually processed and acquired sample data from corresponding PBMC samples are shown for comparison on the right of the graph.

hyde) modifies or destroys many surface epitopes recognized by Ab, the requirement for fixation restricts the Ab clones applicable for staining of the barcoded sample convolute.

Thus, CD45 barcoding should not interfere with the data integrity or biological properties of the barcoded samples, which we confirmed experimentally by demonstrating overall correlation of cell frequency data and signal intensity between barcoded and individually prepared samples. Some deviations were noted in the signal range occupied by sample cells of some mass detection channels, which is certainly a result of the differing Ab saturation conditions in the composite sample (15×10^6 cells, staining volume 50 μ l) versus individual samples (0.75×10^6 cells, staining volume 20 μ l). In addition to the de facto harmonization of sample preparation, including Ab staining, fixation, permeabilization, washing steps, and acquisition conditions on the

CytoF instrument, the deconvolution of the barcode largely depletes cell doublets formed between differently barcoded samples and reduces intrasample doublets. The latter appears to result from the stochastics of how doublet events can be generated. Assuming that the frequency of doublets in a given sample as a function of cell density in the injected cell suspension is constant over its runtime, the likelihood that a detected doublet event in the undeconvoluted data is a doublet formed between two cell events from differently barcoded samples (an intersample doublet) is directly proportional to the number of samples barcoded. Thus, the more samples that are barcoded, the less likely it is to detect a cell doublet that results from two cells of the same sample (an intrasample doublet).

Overall, CD45 barcoding results in a significant clean-up of the data that permits use of largely identical gates in manual analyses

and reduces preprocessing work prior to algorithmic approaches. The doublet removal feature is of particular importance because there are no mass cytometry analogs of light scatter measurements, which are used to identify and remove doublets in conventional flow cytometry. Once cells have been barcoded, liquid handling and reagent consumption are greatly reduced. Small to moderate savings can be expected in CyTOF runtime for the composite sample compared with a series of individually acquired samples, as portions of the composite sample can be successively injected without washing steps between injections. Thus, sample-to-sample carryover problems are largely eliminated. Over the runtime of our composite samples (3–4 h), we did not note major variation in signal intensities of stained cells or metal-loaded beads mixed into the sample. In case of such variation, data can be normalized based on bead signal intensities (9).

Although the approach is designed to work with one of the most abundantly used materials for cellular biomarker research, that is, PBMC, all of which express high levels of CD45, limitations may occur when cell samples are used that express low or heterogeneous levels of CD45, as could be the case with cell lines or non-leukocytes. In such cases, the approach could be rebuilt with Abs better suitable to the particular cell material, with the requirements that the analyte is stably and abundantly expressed and is not expected to be regulated in the different samples that are barcoded, and that high-affinity probes are available. In the case of live PBMC, these requirements are fulfilled with CD45 Ab. Additionally, possible contaminants of PBMC preparations such as residual erythrocytes or thrombocytes do not express CD45, are not stained by the barcoding reagents, and are therefore depleted in the deconvolution, even when they are detected as cell events by staining of their surface receptors. An extremely rare but possible limitation is CD45 deficiency, a rare genetic disorder that causes a SCID phenotype (23). Because CD45 modulates Ag receptor and cytokine signaling (24), binding of cell membrane CD45 with anti-CD45 Ab could influence functional outcome of stimulation assays if barcoding were done prior to stimulation. CD45 expression by all target cells must be confirmed when applying the method to other mononuclear cells of tissues other than blood or certain clinical conditions. For example, some plasma cells of the bone marrow show low CD45 expression, especially in multiple myeloma (25, 26).

Further variations of the protocol can be considered, such as using more or fewer Ab conjugates for barcoding to accommodate different numbers of samples in the barcoded convolute, or modifying the number of labels for the barcoded samples. For example, using five different Abs permits barcoding of 10 samples when each sample carries unique combinations of two labels. Furthermore, CD45 barcoding could be performed using conventional, lanthanide-labeled CD45 Ab, could be applied to MACS- or FACS-based pre-enriched cells, and could likely also be used prior to separation protocols for enrichment of cells in the composite sample. In theory, up to 64 samples could be barcoded to be run as one convolute by giving up the “three-only” strategy; however, such an experiment would not benefit from doublet removal and would be prone to a certain degree of sample cross-contamination.

Considering the relatively low cell throughput on CyTOF instruments, maximizing cell recovery is crucial in studies requiring high throughput. In that regard, the cell recovery from the barcoded convolute was comparable to that of individually acquired samples.

Cell events excluded during the deconvolution due to showing more than three CD45 labels comprise intersample doublets, reflecting both physical aggregates of cells but also the possibility of

two or more cells’ ion clouds hitting the detector in such temporal proximity that the CyTOF software assigns them to one single cell event. Whereas the former parameter depends on properties such as adherence and sample preparation, the latter is a function of cell density in the injected suspension. Cells that show low adherence and that are acquired by CyTOF at low event rate will generate fewer doublet events and minor loss to barcodes with more than three labels. Conversely, cell events assigned to barcodes with less than three CD45 labels comprise cell debris, but may also contain contaminating CD45^{low} cells, that is, non-PBMC.

Although the cell throughput per se cannot be increased with the current instrumentation, improvements of CD45 staining intensities and/or lowering the CV of CD45 staining would lead to a better separation between CD45-stained and unstained cells in the barcode channels and could thereby contribute to enhanced recovery after data deconvolution.

Finally, the concept of using Ab-based barcoding is not limited to mass cytometry but can be likewise applied to flow cytometry experiments. The approach is more feasible with increasing availability of cytometric channels on high-end conventional or continuous spectrum-detecting flow cytometers.

Barcoding using CD45 Abs facilitates increased throughput and multiplexed mass cytometry analyses of human PBMC, and it contributes to data accuracy and comparability in mass cytometry-based biomarker research.

Note added in proof. The authors wish to amend their introduction by mentioning that fluorescently labeled CD45 Ab have been applied to cell surface barcoding before, for multiplexing micro-engraving experiments (27).

Acknowledgments

We are indebted to Eli Zunder for discussions about barcoding strategies and sharing SCN-Bn-EDTA loading procedures. We thank Meena Malipatlolla for technical support.

Disclosures

The authors have no financial conflicts of interest.

References

- Bendall, S. C., E. F. Simonds, P. Qiu, A. D. Amir, P. O. Krutzik, R. Finck, R. V. Bruggner, R. Melamed, A. Trejo, O. I. Ornatsky, et al. 2011. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. *Science* 332: 687–696.
- Tanner, S. D., D. R. Bandura, O. Ornatsky, V. I. Baranov, M. Nitz, and M. A. Winnik. 2008. Flow cytometer with mass spectrometer detection for massively multiplexed single-cell biomarker assay. *Pure Appl. Chem.* 80: 2627–2641.
- Bendall, S. C., G. P. Nolan, M. Roederer, and P. K. Chattopadhyay. 2012. A deep profiler’s guide to cytometry. *Trends Immunol.* 33: 323–332.
- Perfetto, S. P., P. K. Chattopadhyay, and M. Roederer. 2004. Seventeen-colour flow cytometry: unravelling the immune system. *Nat. Rev. Immunol.* 4: 648–655.
- Davis, M. M. 2008. A prescription for human immunology. *Immunity* 29: 835–838.
- Maecker, H. T., J. P. McCoy, and R. Nussenblatt. 2012. Standardizing immunophenotyping for the Human Immunology Project. *Nat. Rev. Immunol.* 12: 191–200.
- Maecker, H. T., J. P. McCoy, Jr., the FOCIS Human Immunophenotyping Consortium. 2010. A model for harmonizing flow cytometry in clinical trials. *Nat. Immunol.* 11: 975–978.
- Leipold, M. D., and H. T. Maecker. 2012. Mass cytometry: protocol for daily tuning and running cell samples on a CyTOF mass cytometer. *J. Vis. Exp.* 2: e4398.
- Finck, R., E. F. Simonds, A. Jager, S. Krishnaswamy, K. Sachs, W. Fantl, D. Pe’er, G. P. Nolan, and S. C. Bendall. 2013. Normalization of mass cytometry data with bead standards. *Cytometry A* 83: 483–494.
- Krutzik, P. O., M. R. Clutter, A. Trejo, and G. P. Nolan. 2011. Fluorescent cell barcoding for multiplex flow cytometry. *Curr. Protoc. Cytom.* Chapter 6: Unit 6.31. doi:10.1002/0471142956.cy0631s55
- Zivanovic, N., A. Jacobs, and B. Bodenmiller. 2014. A practical guide to multiplexed mass cytometry. *Curr. Top. Microbiol. Immunol.* 377: 95–109.
- Gaudilliere, B., G. K. Fragiadakis, R. V. Bruggner, M. Nicolau, R. Finck, M. Tingle, J. Silva, E. A. Ganio, C. G. Yeh, W. J. Maloney, et al. 2014. Clinical recovery from surgery correlates with single-cell immune signatures. *Sci. Transl. Med.* 6: 255ra131.

13. Bodenmiller, B., E. R. Zunder, R. Finck, T. J. Chen, E. S. Savig, R. V. Brugger, E. F. Simonds, S. C. Bendall, K. Sachs, P. O. Krutzik, and G. P. Nolan. 2012. Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. *Nat. Biotechnol.* 30: 858–867.
14. Behbehani, G. K., C. Thom, E. R. Zunder, R. Finck, B. Gaudilliere, G. K. Fragiadakis, W. J. Fantl, and G. P. Nolan. 2014. Transient partial permeabilization with saponin enables cellular barcoding prior to surface marker staining. *Cytometry A* 85: 1011–1019.
15. Becher, B., A. Schlitzer, J. Chen, F. Mair, H. R. Sumatoh, K. W. Teng, D. Low, C. Ruedl, P. Riccardi-Castagnoli, M. Poidinger, et al. 2014. High-dimensional analysis of the murine myeloid cell system. *Nat. Immunol.* 15: 1181–1189.
16. Zunder, E. R., R. Finck, G. K. Behbehani, E. D. Amir, S. Krishnaswamy, V. D. Gonzales, C. G. Lorang, Z. Bjornson, M. H. Spitzer, B. Bodenmiller, et al. 2014. Palladium-based mass-tag cell barcoding with a doublet-filtering scheme and single cell deconvolution algorithm. *Nat. Protoc.* DOI: 10.1038/nprot.2015.020.
17. Majonis, D., O. Ornatsky, R. Kinach, and M. A. Winnik. 2011. Curious results with palladium- and platinum-carrying polymers in mass cytometry bioassays and an unexpected application as a dead cell stain. *Biomacromolecules* 12: 3997–4010.
18. Fienberg, H. G., E. F. Simonds, W. J. Fantl, G. P. Nolan, and B. Bodenmiller. 2012. A platinum-based covalent viability reagent for single-cell mass cytometry. *Cytometry A* 81: 467–475.
19. Ziegler-Heitbrock, L., P. Ancuta, S. Crowe, M. Dalod, V. Grau, D. N. Hart, P. J. Leenen, Y. J. Liu, G. MacPherson, G. J. Randolph, et al. 2010. Nomenclature of monocytes and dendritic cells in blood. *Blood* 116: e74–e80.
20. Krutzik, P. O., and G. P. Nolan. 2006. Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling. *Nat. Methods* 3: 361–368.
21. Frischbutter, S., K. Schultheis, M. Pätzelt, A. Radbruch, and R. Baumgrass. 2012. Evaluation of calcineurin/NFAT inhibitor selectivity in primary human Th cells using bar-coding and phospho-flow cytometry. *Cytometry A* 81: 1005–1011.
22. Simard, C., M. Cloutier, and S. Néron. 2014. Feasibility study: phosphospecific flow cytometry enabling rapid functional analysis of bone marrow samples from patients with multiple myeloma. *Cytometry B Clin. Cytom.* 86: 139–144.
23. Kung, C., J. T. Pingel, M. Heikinheimo, T. Klemola, K. Varkila, L. I. Yoo, K. Vuopala, M. Poyhonen, M. Uhari, M. Rogers, et al. 2000. Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease. *Nat. Med.* 6: 343–345.
24. Penninger, J. M., J. Irie-Sasaki, T. Sasaki, and A. J. Oliveira-dos-Santos. 2001. CD45: new jobs for an old acquaintance. *Nat. Immunol.* 2: 389–396.
25. Pellat-Deceunynck, C., and R. Bataille. 2004. Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression. *Blood Cells Mol. Dis.* 32: 293–301.
26. Schneider, U., A. van Lessen, D. Huhn, and S. Serke. 1997. Two subsets of peripheral blood plasma cells defined by differential expression of CD45 antigen. *Br. J. Haematol.* 97: 56–64.
27. Yamanaka, Y. J., G. L. Szeto, T. M. Gierahn, T. L. Forcier, K. F. Benedict, M. S. Brefo, D. A. Lauffenburger, D. J. Irvine, and J. C. Love. 2012. Cellular barcodes for efficiently profiling single-cell secretory responses by micro-engraving. *Anal. Chem.* 84: 10531–10536.